Vilaprisan for treating uterine fibroids

Area of Science:

• Reproductive endocrinology and pharmacology
• Gynecological therapeutics

Background:

• Medical management of uterine fibroids (myomas) targets reducing estrogen and progesterone activity.
• Selective progesterone receptor modulators (SPRMs) offer tissue-specific agonist/antagonist effects on the progesterone receptor (PR).
• Ulipristal acetate (UPA) is an established SPRM for fibroid treatment, with vilaprisan representing a novel, potent SPRM.

Purpose of the Study:

• To evaluate the efficacy and safety of vilaprisan, a novel SPRM, for treating symptomatic uterine fibroids.
• To compare the speed of action and side effect profile of vilaprisan with existing treatments like GnRH agonists (GnRHa).

Main Methods:

• Review of Phase I and II clinical studies on vilaprisan for uterine fibroid treatment.
• Assessment of vilaprisan's impact on heavy uterine bleeding, myoma size, and endometrial changes.
• Comparison of vilaprisan's effects with GnRH agonists and ulipristal acetate, focusing on hypoestrogenism and symptom control.

Main Results:

• Vilaprisan demonstrates encouraging efficacy in Phase I and II studies at various doses.
• Vilaprisan achieves rapid control of myoma-related bleeding, with significant reduction observed within three days.
• Unlike GnRH agonists, vilaprisan does not induce hypoestrogenism or associated symptoms.
• Vilaprisan induces benign PR modulator-associated endometrial changes (PAECs) that resolve post-treatment.

Conclusions:

• Vilaprisan is a potent SPRM with rapid and effective control of uterine fibroid bleeding.
• Vilaprisan offers a favorable safety profile by avoiding hypoestrogenism, distinguishing it from GnRH agonist therapy.
• Ongoing Phase III studies are crucial to confirm vilaprisan's long-term efficacy and safety for symptomatic fibroids.